Sign in
4

Changes in Ownership

Ensysce Biosciences, Inc. Filed Acc 0001493152-22-003204

Options or other derivatives

  • Chief Financial Officer acquired 275,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Humphrey David Carl Chief Financial Officer 2022-02-04 Grant or award · Stock Option +275,000 275,000 D
Loading xslF345X03/ownership.xml…